Table 2 Parasitemia level and leukocyte differential counts in co-infections and Plasmodium mono-infections.

From: A meta-analysis on the prevalence and characteristics of severe malaria in patients with Plasmodium spp. and HIV co-infection

No.

Author, year

Parasitemia level (cells/µL)

Leukocyte counts (103 cells/µL)

Neutrophil counts (103 cells/µL)

Lymphocyte counts (103 cells/µL)

Co-infection

Plasmodium mono-infection

Co-infection

Plasmodium mono-infection

Co-infection

Plasmodium mono-infection

Co-infection

Plasmodium mono-infection

1.

Addissie et al. (2007)21

NA

NA

NA

NA

NA

NA

NA

NA

2.

Amodu-Sanni et al. (2020)22

NA

NA

NA

NA

NA

NA

NA

NA

3.

Berg et al. (2014)2

NA

NA

NA

NA

NA

NA

NA

NA

4.

Berg et al. (2008)23

NA

NA

NA

NA

NA

NA

NA

NA

5.

Berg et al. (2020)24

NA

NA

NA

NA

NA

NA

NA

NA

6.

Berkley et al. (2009)25

37,500 (2680–172,150) (n = 133)

22,352 (2213–142,590) (n = 938)

NA

NA

NA

NA

NA

NA

7.

Beyene et al. (2017)26

NA

NA

NA

NA

NA

NA

NA

NA

8.

Bronzan et al. (2007)27

52,048 (n = 178)

40,356 (n = 941)

10.5

11.4

NA

NA

NA

NA

9.

Chalwe et al. (2009)28

43,314 (25,467–81,145) (n = 27)

11,745 and 38,942 (n = 2)

6.9 (3.9)

4.2 and 8.7

NA

NA

1.73 (0.43)

1.16 (0.58)

10.

Cohen et al. (2005)15

NA

NA

NA

NA

NA

NA

NA

NA

11.

Davenport et al. (2010)29

16,220 (43,127) (n = 24)

22,281 (51,064) (n = 406)

13.3 (8.4)

11.2 (6.6)

35.6 (21.1)

41.0 (22.8)

49.4 (16.7)

50.0 (19.2)

12.

Grimwade et al. (2004)42

NA

NA

NA

NA

NA

NA

NA

NA

13.

Hendriksen et al. (2012)30

Aged < 15: 47,141 (38,005–58,474) (n = 74)

Aged ≥ 15: 133,653 (59,082–302,343) (n = 581)

Aged < 15: 68,320 (37,680–123,874) (n = 49)

Aged ≥ 15: 61,525 (24,628–153,704) (n = 19)

NA

NA

NA

NA

NA

NA

14.

Hochman et al. (2015)31

CM1: 98,300 (48,200–324,800) (n = 7)

CM2: 56,400 (28,800–308,700) (n = 7)

CM1: 49,200 (5,100–717,600) (n = 5)

CM2: 13,200 (7,500–433,300) (n = 33)

CM1: 14.5 (12.1–17.1)

CM2: 13.2 (10.9–19.3)

CM1: 11.2 (7.3–15.7)

CM2: 12.4 (9.1–21.5)

NA

NA

CM1: 2.4 (1.5, 5.1)

CM2: 2.7 (1.5–5.3)

CM1: 2.3 (2–5.5)

CM2: 5.3 (2.2–7.8)

15.

Huson et al. (2015)32

54,000 (17,340–134,700) (n = 14)

4,740 (1,300–

18,300) (n = 113)

5.1 (3.3–6.6)

5.3 (3.9–7.2)

NA

NA

NA

NA

16.

Imani et al. (2011)43

Cerebral malaria

240,000 (3080–583,520) (n = 9)

Cerebral malaria

21,440 (1600–133,080) (n = 91)

NA

NA

NA

NA

NA

NA

17.

Jacques et al. (2019)33

NA

NA

NA

NA

NA

NA

NA

NA

18.

Joice et al. (2016)34

20,200 (2900–32,500) (n = 20)

7400 (800–42,400) (n = 75)

13.6 (11.9–14.7)

11.2 (8.8–18.4)

NA

NA

NA

NA

19.

Kyeyune et al. (2014)44

NA

NA

NA

NA

NA

NA

NA

NA

20.

Mandala et al. (2018)35

NA

NA

10.20 (7.85–13.75) (n = 9)

11.20 (7.90–15.30) (n = 29)

6.30 (5.23–12.35)

7.40 (4.6–12.50)

1.10 (0.85–1.73)

2.01 (1.50–3.2)

21.

Mouala et al. (2008)36

NA

NA

NA

NA

NA

NA

NA

NA

22.

Munyenyembe et al. (2018)37

NA

NA

Severe malaria 6.15 (2.9–14.2) (n = 12), uncomplicated malaria 4.3 (2.4–9) (n = 18)

Severe malaria 5 (2.4–7.25) (18), uncomplicated malaria 5.6 (3.9–10.5) (n = 58)

Severe malaria 3.46 (0.9–12.4), uncomplicated malaria 2.25 (2.1–4.1)

Severe malaria 2.72 (1.1–3.74), uncomplicated malaria 3.03 (1.7–7.7)

Severe malaria 2.25 (1.1–2.8), uncomplicated malaria 1.4 (0.62–3.15)

Severe malaria 1.26 (0.6–3.3), uncomplicated malaria 1.58 (0.74–3.04)

23.

Niyongabo et al. (1994)45

NA

NA

NA

NA

NA

NA

NA

NA

24.

Nkuo-Akenji et al. (2008)38

NA

NA

NA

NA

NA

NA

NA

NA

25.

Otieno et al. (2006)46

NA

NA

NA

NA

NA

NA

NA

NA

26.

Sandie et al. (2019)39

NA

NA

NA

NA

NA

NA

NA

NA

27.

Saracino et al. (2012)40

1.8 ± 1.1 (n = 51)

2.3 ± 1.2 (n = 39)

7.7 ± 2.5

7.7 ± 3.7

NA

NA

NA

NA

28.

Tagoe DNA and Boachie (2012)41

NA

NA

NA

NA

NA

NA

NA

NA

29.

Tay et al. (2015)17

NA

NA

NA

NA

NA

NA

NA

NA

  1. NA not applicable.